(Q53584625)

15 May 2018

title

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. (English)

1 reference

15 May 2018

main subject

phase II clinical trial

0 references

3

Alexia Iasonos

1 reference

15 May 2018

author name string

Matthew D Galsky

1

1 reference

15 May 2018

Svetlana Mironov

2

1 reference

15 May 2018

Joseph Scattergood

4

1 reference

15 May 2018

Mary G Boyle

5

1 reference

15 May 2018

Dean F Bajorin

6

1 reference

15 May 2018

publication date

5 December 2006

1 reference

15 May 2018

Investigational New Drugs

published in

1 reference

15 May 2018

volume

25

1 reference

15 May 2018

page(s)

265-270

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1007/s10637-006-9020-9

exact match

0 references

cites work

Pemetrexed in bladder, head and neck, and cervical cancers

1 reference

12 December 2020

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy

1 reference

12 December 2020

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

12 December 2020

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

12 December 2020

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

12 December 2020

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

12 December 2020

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

12 December 2020

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

12 December 2020

Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

12 December 2020

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.

1 reference

12 December 2020

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

12 December 2020

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function

1 reference

12 December 2020

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

12 December 2020

10.1007/S10637-006-9020-9

Identifiers

DOI

1 reference

15 May 2018

PubMed ID

17146733

1 reference

15 May 2018